X

Trial Profile

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 03 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Goflikicept (Primary)
Indications Pericarditis
Focus Therapeutic Use
Sponsors R-Pharm

Most Recent Events

04 Jul 2023 Results published in the Journal of the American College of Cardiology
27 Oct 2022 Status changed from recruiting to completed.
04 Jun 2022 Interim results assessing the efficacy and safety of goflikicept treatment in patients with IRP presented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com